RxDoctor Payments Data

Jeff Banas, OD

Optometrist · Mount Pleasant, WINPI 1619328606

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 22.0%. 2025 is the largest year on record at $26,221, more than ten times the $399 reported in 2019. Among optometrist clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$46,487in general payments, 2019–2025

Across 304 payments — averaging $152.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$10K
  • Nordic Pharma, Inc.$7K
  • Alcon$7K
  • Glaukos Corporation$6K
  • Carl Zeiss Meditec USA, Inc.$3K
  • Rxsight Inc$2K
  • plus $11K from 22 others

What the payments were for

  • Consulting fees$20,23944%
  • Speaking & faculty fees$9,62621%
  • Travel & lodging$5,06411%
  • Food & beverage$11,44825%
  • Education$1110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,487 in reported general payments places this provider in the 95th percentile of 867 optometrist providers in Wisconsin.

See all optometrist providers in Wisconsin

Medicare billing

Part B allowed, 2024
$120,007
Medicare patients
529
Services billed
1,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine216$210,829
LumiganBimatoprost169$71,299
Cyclosporine74$52,418
XiidraLifitegrast40$41,367
CombiganBrimonidine Tartrate/Timolol113$37,748
VyzultaLatanoprostene Bunod85$37,378
RocklatanNetarsudil Mesylat/Latanoprost78$29,194
SimbrinzaBrinzolamide/Brimonidine Tart110$27,199
XdemvyLotilaner12$24,184
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol143$18,370
CequaCyclosporine20$17,475
TyrvayaVarenicline Tartrate20$15,371
ProlensaBromfenac Sodium38$13,521
IlevroNepafenac34$13,097
RhopressaNetarsudil Mesylate18$10,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Restasis Multidose$2,366$328,444513 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$10,230$78,745125 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$31$40,17196 claims
AlconSimbrinza$6,950$27,199110 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$1,486$24,18412 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm$60$18,80059 claims
Sun Pharmaceutical Industries Inc.Cequa$369$17,47520 claims
Oyster Point Pharma, Inc.Tyrvaya$312$15,37120 claims
NovartisIlevro$598$13,09734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 867 optometrist providers in Wisconsin.

Other optometrist in Mount Pleasant

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →